Phase I Trial of Fludarabine and Methoxyamine (TRC102) for Relapsed or Refractory Hematologic Malignancies

Trial Profile

Phase I Trial of Fludarabine and Methoxyamine (TRC102) for Relapsed or Refractory Hematologic Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs TRC 102 (Primary) ; Fludarabine
  • Indications Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 23 Apr 2015 Planned End Date changed from 1 Jan 2015 to 1 Sep 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top